SG11201909429VA - 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections - Google Patents
3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infectionsInfo
- Publication number
- SG11201909429VA SG11201909429VA SG11201909429VA SG11201909429VA SG 11201909429V A SG11201909429V A SG 11201909429VA SG 11201909429V A SG11201909429V A SG 11201909429VA SG 11201909429V A SG11201909429V A SG 11201909429VA
- Authority
- SG
- Singapore
- Prior art keywords
- oxy
- international
- beta
- suite
- palo alto
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT omit VIII °nolo Holollm H H voila° oimIE (10) International Publication Number WO 2018/208557 Al (51) International Patent Classification: C07D 471/08 (2006.01) A61P 31/04 (2006.01) A61K 31/439 (2006.01) (21) International Application Number: PCT/US2018/030652 (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) W O 20 18/ 208557 Al 02 May 2018 (02.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/504,523 10 May 2017 (10.05.2017) US 62/551,043 28 August 2017 (28.08.2017) US 15/934,497 23 March 2018 (23.03.2018) US (71) Applicant: ARIXA PHARMACEUTICALS, INC. [US/US]; 525 Univercity Ave., Suite 1350, Palo Alto, CA 94301 (US). (72) Inventors: GORDON, Eric, M.; 525 University Ave., Suite 1350, Palo Alto, CA 94301 (US). FREUND, John; 525 University Ave., Suite 1350, Palo Alto, CA 94301 (US). GALLOP, Mark, A.; 525 University Ave., Suite 1350, Pa- lo Alto, CA 94301 (US). DUNCTON, Matthew, Alexan- der, James; 525 University Ave., Suite 1350, Palo Alto, CA 94301 (US). (74) Agent: LAMBERT, William, R.; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Ave., Palo Alto, CA 94301 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: 3 -(((((2 S,5R)-2-CARBAMOYL-7-0X0-1,6-DIAZABICYCLO [3 .2 .1] OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2 - DIMETHYLPROP NOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS (57) : 3-(((((25,5R)-2-carbamoy1-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-y1) oxy)sulfonyl)oxy)-2,2-dimethylpropanoate deriv- atives and related compounds as perorally administered prodrugs of beta-lactamase inhibitors for treating bacterial infections, particu- larly in combination with beta-lactam antibiotics.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504523P | 2017-05-10 | 2017-05-10 | |
| US201762551043P | 2017-08-28 | 2017-08-28 | |
| US15/934,497 US10085999B1 (en) | 2017-05-10 | 2018-03-23 | Beta-lactamase inhibitors and uses thereof |
| PCT/US2018/030652 WO2018208557A1 (en) | 2017-05-10 | 2018-05-02 | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909429VA true SG11201909429VA (en) | 2019-11-28 |
Family
ID=63639355
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909429V SG11201909429VA (en) | 2017-05-10 | 2018-05-02 | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections |
| SG10202102306TA SG10202102306TA (en) | 2017-05-10 | 2018-05-02 | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102306TA SG10202102306TA (en) | 2017-05-10 | 2018-05-02 | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10085999B1 (en) |
| EP (1) | EP3625233B9 (en) |
| JP (2) | JP6909924B2 (en) |
| KR (1) | KR102411517B1 (en) |
| CN (1) | CN110662746B (en) |
| AU (2) | AU2018266566B2 (en) |
| BR (1) | BR112019023598A2 (en) |
| CA (2) | CA3062619C (en) |
| DK (1) | DK3625233T5 (en) |
| ES (1) | ES2955871T3 (en) |
| FI (1) | FI3625233T5 (en) |
| HR (1) | HRP20230977T1 (en) |
| HU (1) | HUE062752T2 (en) |
| IL (2) | IL296379A (en) |
| LT (1) | LT3625233T (en) |
| MX (2) | MX2019013260A (en) |
| PL (1) | PL3625233T3 (en) |
| PT (1) | PT3625233T (en) |
| RS (1) | RS64547B9 (en) |
| RU (1) | RU2753401C2 (en) |
| SG (2) | SG11201909429VA (en) |
| SI (1) | SI3625233T1 (en) |
| WO (1) | WO2018208557A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| JP6991345B2 (en) | 2017-10-02 | 2022-01-12 | アリクサ ファーマシューティカルズ、インコーポレイテッド | Aztreonam derivatives and their use |
| CA3114618C (en) | 2018-10-01 | 2023-09-05 | Arixa Pharmaceuticals, Inc. | Derivatives of relebactam and uses thereof |
| WO2020185729A1 (en) | 2019-03-12 | 2020-09-17 | Arixa Pharmaceuticals, Inc. | Crystalline form of an avibactam derivative |
| WO2020219405A1 (en) * | 2019-04-26 | 2020-10-29 | Merck Sharp & Dohme Corp. | Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
| CN114302725A (en) * | 2019-08-29 | 2022-04-08 | 阿里萨制药公司 | Oral administration combination of beta lactam antibiotic and avibactam derivative for the treatment of bacterial infections |
| US20210186983A1 (en) | 2019-12-20 | 2021-06-24 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections |
| CN111943950B (en) * | 2020-09-10 | 2022-03-29 | 山东安信制药有限公司 | Preparation method of rilibatan |
| BR112023020348A2 (en) * | 2021-04-05 | 2023-11-21 | Qpex Biopharma Inc | CEFTIBUTENE DOSAGE REGIMES |
| CN115448920A (en) * | 2022-10-14 | 2022-12-09 | 广州楷石医药有限公司 | Beta-lactamase inhibitor and application thereof |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3658849A (en) | 1969-02-19 | 1972-04-25 | Reynolds Tobacco Co R | Treatment of 2-substituted aldehydes with lead dioxide |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3045373A1 (en) | 1980-12-02 | 1982-07-01 | Henkel KGaA, 4000 Düsseldorf | Use of 3-hydroxy-2,2-di:methyl-propionate ester(s) as fragrances - including new propyl ester |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (en) | 1990-04-17 | 1994-11-18 | Eurand Int | METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (en) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | Delayed release microsphere of drug |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| AU722289B2 (en) | 1996-10-01 | 2000-07-27 | Aptalis Pharmatech, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ATE272394T1 (en) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | DELAYED RELEASE PREPARATION |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| ATE233088T1 (en) | 1996-12-20 | 2003-03-15 | Takeda Chemical Industries Ltd | METHOD FOR PREPARING A DELAYED RELEASE COMPOSITION |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| CN1199686C (en) | 1998-01-16 | 2005-05-04 | 武田药品工业株式会社 | Sustained release compositions, process for producing the same and utilization thereof |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (en) | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| FR2812635B1 (en) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS |
| WO2002092606A1 (en) | 2001-05-15 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Fused imidazolidine derivatives, process for preparation of the same and use thereof |
| WO2005025506A2 (en) | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| UY30244A1 (en) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | A PROCESS TO PREPARE DERIVATIVES OF TETRAHYDROQUINOLINE |
| TW200924746A (en) | 2007-09-07 | 2009-06-16 | Xenoport Inc | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009052191A1 (en) | 2007-10-15 | 2009-04-23 | Xenoport, Inc. | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| SI2231667T1 (en) | 2008-01-18 | 2013-12-31 | Merck Sharp & Dohme Corp. | Beta-lactamase inhibitors |
| GB0801401D0 (en) | 2008-01-25 | 2008-03-05 | Barry Callebaut Ag | Composition |
| US8987468B2 (en) | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| JP5524215B2 (en) | 2008-09-19 | 2014-06-18 | ファイザー・インク | Hydroxamic acid derivatives useful as antibacterial agents |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| UA109417C2 (en) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | Substituted piperidines, which improve activity of p53, and use thereof |
| LT2562155T (en) | 2010-04-20 | 2019-08-12 | Taisho Pharmaceutical Co., Ltd. | Hydroxamic acid derivative |
| US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| DE102010033015B4 (en) | 2010-07-31 | 2016-03-17 | Gaplast Gmbh | Single-use applicator |
| EP2657234B1 (en) | 2010-12-22 | 2017-01-11 | Meiji Seika Pharma Co., Ltd. | Optically-active diazabicyclooctane derivative and method for manufacturing same |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| AU2012263327B2 (en) | 2011-05-30 | 2015-07-09 | Sumitomo Chemical Company, Limited | Cyclohexanone compounds and herbicides comprising the same |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| AR090539A1 (en) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | INHIBITING COMPOUNDS OF B LACTAMASA |
| EP2857401B8 (en) * | 2012-05-30 | 2019-11-20 | Meiji Seika Pharma Co., Ltd. | NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME |
| KR102173632B1 (en) | 2014-04-18 | 2020-11-03 | 욱크하르트 리미티드 | Pharmaceutical compositions comprising antibacterial agents |
| KR20170048546A (en) | 2014-09-12 | 2017-05-08 | 토야마 케미칼 컴퍼니 리미티드 | Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof |
| KR20170047390A (en) | 2014-09-12 | 2017-05-04 | 토야마 케미칼 컴퍼니 리미티드 | Method for using novel hydroxamic acid derivative and antibacterial substance in combination |
| WO2016116788A1 (en) | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| WO2017037607A1 (en) * | 2015-09-01 | 2017-03-09 | Wockhardt Limited | (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity |
| MX2017013792A (en) * | 2015-09-16 | 2018-07-06 | Xuanzhu Pharma Co Ltd | íŸ-LACTAMASE INHIBITOR AND APPLICATION THEREOF. |
| US20170165371A1 (en) | 2017-02-22 | 2017-06-15 | Joel Steven Goldberg | Novel synthesis of potential ester prodrugs |
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
-
2018
- 2018-03-23 US US15/934,497 patent/US10085999B1/en active Active
- 2018-05-02 CA CA3062619A patent/CA3062619C/en active Active
- 2018-05-02 DK DK18729223.0T patent/DK3625233T5/en active
- 2018-05-02 SI SI201830972T patent/SI3625233T1/en unknown
- 2018-05-02 LT LTEPPCT/US2018/030652T patent/LT3625233T/en unknown
- 2018-05-02 IL IL296379A patent/IL296379A/en unknown
- 2018-05-02 ES ES18729223T patent/ES2955871T3/en active Active
- 2018-05-02 PT PT187292230T patent/PT3625233T/en unknown
- 2018-05-02 CN CN201880030530.7A patent/CN110662746B/en active Active
- 2018-05-02 FI FIEP18729223.0T patent/FI3625233T5/en active
- 2018-05-02 SG SG11201909429V patent/SG11201909429VA/en unknown
- 2018-05-02 BR BR112019023598-1A patent/BR112019023598A2/en unknown
- 2018-05-02 KR KR1020197036316A patent/KR102411517B1/en active IP Right Grant
- 2018-05-02 CA CA3153583A patent/CA3153583A1/en active Pending
- 2018-05-02 JP JP2020512764A patent/JP6909924B2/en active Active
- 2018-05-02 EP EP18729223.0A patent/EP3625233B9/en active Active
- 2018-05-02 HR HRP20230977TT patent/HRP20230977T1/en unknown
- 2018-05-02 WO PCT/US2018/030652 patent/WO2018208557A1/en active Application Filing
- 2018-05-02 SG SG10202102306TA patent/SG10202102306TA/en unknown
- 2018-05-02 RU RU2019135891A patent/RU2753401C2/en active
- 2018-05-02 AU AU2018266566A patent/AU2018266566B2/en active Active
- 2018-05-02 PL PL18729223.0T patent/PL3625233T3/en unknown
- 2018-05-02 RS RS20230696A patent/RS64547B9/en unknown
- 2018-05-02 MX MX2019013260A patent/MX2019013260A/en unknown
- 2018-05-02 HU HUE18729223A patent/HUE062752T2/en unknown
- 2018-08-29 US US16/116,489 patent/US10500211B2/en active Active
-
2019
- 2019-10-16 US US16/654,281 patent/US10722521B2/en active Active
- 2019-10-31 IL IL270330A patent/IL270330B2/en unknown
- 2019-11-06 MX MX2021008379A patent/MX2021008379A/en unknown
-
2020
- 2020-06-08 US US16/895,033 patent/US20200297733A1/en not_active Abandoned
- 2020-09-03 AU AU2020227077A patent/AU2020227077B2/en active Active
-
2021
- 2021-07-05 JP JP2021111184A patent/JP2021165298A/en active Pending
-
2023
- 2023-02-28 US US18/176,048 patent/US20230201218A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909429VA (en) | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201907335UA (en) | Aminotriazolopyridines as kinase inhibitors | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908351TA (en) | Indole derivatives as efflux pump inhibitors | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201408171SA (en) | Fbxo3 inhibitors |